(MedPage Today) — The FDA approved taletrectinib (Ibtrozi) — a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) — for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)…
Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116021
Author :
Publish date : 2025-06-11 20:19:00
Copyright for syndicated content belongs to the linked Source.
